


Annex

COVID-19 Vaccine Development Timeline



Abbreviations: COVAX, COVID-19 Vaccines Global Access; EUA, emergency use authorization; EUL, emergency use listing; FDA, Food and Drug Administration; MHRA, Medicine and Healthcare Products Regulatory Agency; SII, Serum Institute of India; SRA, stringent regulatory authority; WHO, World Health Organization.

References

- Moderna. Moderna announces first participant dosed in NIH-led Phase 1 study of mRNA vaccine (mRNA-1273) against novel coronavirus. Published March 16, 2020. Accessed October 27, 2021. <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participant-dosed-nih-led-phase-1-study/>
- Moderna. Moderna announces first participants in each age cohort dosed in Phase 2 study of mRNA vaccine (mRNA-1273) against novel coronavirus. Published May 29, 2020. Accessed October 27, 2021. <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-each-age-cohort-dosed-phase/>
- Moderna. Moderna completes enrollment of Phase 3 COVE Study of mRNA vaccine against COVID-19 (mRNA-1273). Published October 22, 2020. Accessed October 27, 2021. <https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-enrollment-phase-3-cove-study-mrna-vaccine/>
- Moderna. Moderna announces primary efficacy analysis in Phase 3 COVE Study for its COVID-19 vaccine candidate and filing today with U.S. FDA for emergency use authorization. Published November 30, 2020. Accessed October 27, 2021. <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study/>
- US Food and Drug Administration. Moderna COVID-19 vaccine. Accessed October 21, 2021. <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine>
- World Health Organization (WHO). WHO lists Moderna vaccine for emergency use. Published April 30, 2021. Accessed October 27, 2021. <https://www.who.int/news/item/30-04-2021-who-lists-moderna-vaccine-for-emergency-use>
- Pfizer. BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany. Published April 29, 2020. Accessed October 27, 2021. <https://www.pfizer.com/news/press-release/press-release-detail/biontech-and-pfizer-announce-completion-dosing-first-cohort>
- Pfizer. Pfizer and BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. Published November 18, 2020. Accessed October 27, 2021. <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine>
- Pfizer. Pfizer and BioNTech to submit emergency use authorization request today to the U.S. FDA for COVID-19 vaccine. Published November 20, 2020. Accessed October 27, 2021. <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization>
- United Kingdom Medicines and Healthcare products Regulatory Agency. UK medicines regulator gives approval for first UK COVID-19 vaccine. GOV.UK. Published December 2, 2020. Accessed October 19, 2021. <https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine>
- World Health Organization (WHO). WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access. Published December 31, 2020. Accessed October 27, 2021. <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- Sadoff J, Gars ML, Shukarev G, et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. *N Engl J Med.* 2021;384(19):1824-1835.
- Johnson & Johnson. Johnson & Johnson announces its first Phase 3 COVID-19 vaccine trial ENSEMBLE is fully enrolled. Published December 17, 2020. Accessed October 27, 2021. <https://www.jnj.com/our-company/johnson-johnson-announces-its-first-phase-3-covid-19-vaccine-trial-ensemble-is-fully-enrolled>
- Johnson & Johnson. Johnson & Johnson announces submission of application to the U.S. FDA for emergency use authorization of its investigational single-shot Janssen COVID-19 vaccine candidate. Accessed October 27, 2021. <https://www.jnj.com/johnson-johnson-announces-submission-of-application-to-the-u-s-fda-for-emergency-use-authorization-of-its-investigational-single-shot-janssen-covid-19-vaccine-candidate>
- US Food and Drug Administration (FDA). FDA issues emergency use authorization for third COVID-19 vaccine. Published February 27, 2021. Accessed October 27, 2021. <https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine>
- World Health Organization (WHO). WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19. Published March 12, 2021. Accessed October 27, 2021. <https://www.who.int/news/item/12-03-2021-who-adds-janssen-vaccine-to-list-of-safe-and-effective-emergency-tools-against-covid-19>
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet.* 2020;396(10249):467-478.
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet.* 2021;397(10269):99-111.
- AstraZeneca. AstraZeneca's COVID-19 vaccine authorised for emergency supply in the UK. Published December 30, 2020. Accessed October 27, 2021. <https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html>
- World Health Organization (WHO). WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out. Published February 15, 2021. Accessed October 27, 2021. <https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out>
- Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, Phase 1/2 trial. *Lancet Infect Dis.* 2021;21(1):39-51.
- Chinese Clinical Trial Registry (ChiCTR). A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells). Published July 18, 2020. Accessed October 27, 2021. <http://www.chictr.org.cn/showproj.aspx?proj=56651>
- Daventry M. Hungary becomes first country in the EU to approve a COVID-19 vaccine from China. *euronews.* Updated January 29, 2021. Accessed October 27, 2021. <https://www.euronews.com/2021/01/29/hungary-becomes-the-first-country-in-the-eu-to-approve-a-covid-19-vaccine-from-china>
- World Health Organization (WHO). WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations. Published May 7, 2021. Accessed October 27, 2021. <https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations>